FDA-approved GLP-1 agonist for sustainable, medically-supervised weight loss.
Semaglutide is a GLP-1 receptor agonist (the active ingredient in Ozempic® and Wegovy®) approved for type 2 diabetes and chronic weight management. VitaFlow's program pairs weekly injections with physician oversight, nutrition guidance and body-composition tracking to protect lean mass.
Weekly subcutaneous self-injection with a stepwise dose escalation starting at 0.25 mg. Monthly follow-ups track weight, labs, side effects and body composition.
GLP-1 receptor agonism slows gastric emptying, enhances insulin secretion, suppresses glucagon and acts centrally on appetite regulation in the hypothalamus.
Contraindicated in personal or family history of medullary thyroid carcinoma or MEN2. Common: nausea, constipation, reflux — usually dose-related and transient. Monitor for pancreatitis and gallbladder disease.
This page is educational and not medical advice. All VitaFlow protocols require evaluation by a licensed Florida physician.
STEP trial data averages ~15% at 68 weeks; individual results vary.
Some lean mass loss is expected. Our program includes protein guidance, amino IVs and resistance-training support.
Duration is individualized; many patients use it 6–18 months with a maintenance plan.
Regain is common without continued lifestyle change — our program plans for the exit.
Coverage varies; we offer transparent self-pay pricing.
Meet with a VitaFlow physician to design a protocol tailored to your goals, biomarkers, and lifestyle.
